Xolair (omalizumab) (Subcutaneous) — Concomitant therapy restrictions and dosing guidance
Customize your policy alerts
Sign up for eocco Policy M-P0146 alerts
Get alerted when Policy M-P0146 changes without checking for updates manually.
Monitor payer policy activity
Lists agents that are contraindicated for concurrent use with subcutaneous omalizumab (Xolair) under this payer policy; applicable to providers requesting coverage or administering Xolair.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.